This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Soelberg Sorensen, P. Search for Related Content Social Bookmarking                   What's this?

Review: Neutralizing antibodies against interferon-beta

Danish Multiple Sclerosis Research Center Department of Neurology 2082, Copenhagen University Hospital Rigshospitalet, DK-2100 Copenhagen, Denmark, pss{at}rh.dk

The development of neutralizing antibodies (NAbs) is a major problem in multiple sclerosis (MS) patients treated with interferon-beta (IFN-β). Whereas binding antibodies (BAbs) can be demonstrated in the vast majority of patients, only a smaller proportion of patients develop NAbs. The principle in NAb in vitro assays is the utilization of cultured cell lines that are responsive to IFN-β. The cytopathic effect (CPE) assay measures the capacity of NAbs to neutralize IFN-β's protective effect on cells challenged with virus and the MxA induction assay measures the ability of NAbs to reduce the IFN-β-induced expression of MxA, either at the mRNA or the protein level. A titer of 20 neutralizing units/ml traditionally defines NAb positivity. NAbs in high titers completely abrogate the in vivo response to IFN-β, whereas the effect of low and intermediate titers is unpredictable. As clinically important NAbs appear only after 9—18 months IFN-β therapy, short-term studies of two years or less are unsuitable for evaluation of clinical NAb effects. All long-term trials of three years or more concordantly show evidence of a detrimental effect of NAbs on relapses, disease activity on MRI, or on disease progression. Persistent high titers of NAbs indicate an abrogation of the biological response and, hence, absence of therapeutic efficacy, and this observation should lead to a change of therapy. As low and medium titers are ambiguous treatment decisions in patients with low NAb titres should be guided by determination of in vivo mRNA MxA induction and clinical disease activity.

Key Words: multiple sclerosis • interferon-beta • binding antibodies • neutralizing antibodies • anti-interferon antibodies • bioactivity

Therapeutic Advances in Neurological Disorders, Vol. 1, No. 2, 125-141 (2008)
DOI: 10.1177/1756285608095144


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?